Fuso Pharmaceutical Industries,Ltd. (JP:4538)
:4538
Want to see JP:4538 full AI Analyst Report?
4538 Stock Chart & Stats
¥2315.00
-¥64.00(-2.54%)
At close: 4:00 PM EST
¥2315.00
-¥64.00(-2.54%)
Day’s Range― - ―
52-Week Range¥2,070.00 - ¥2,530.00
Previous CloseN/A
Volume28.90K
Average Volume (3M)17.49K
Market Cap
¥20.11B
Enterprise Value¥42.30B
Total Cash (Recent Filing)¥3.16B
Total Debt (Recent Filing)¥28.23B
Price to Earnings (P/E)5.8
Beta0.62
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.71%
Share Statistics
EPS (TTM)99.84
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.63
Price to Sales (P/S)0.34
P/FCF Ratio-3.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Margin TrendsConsistent revenue growth with improving gross and net margins indicates durable demand and improving operational control. Over 2-6 months this supports cash generation potential if cash conversion improves, underpins reinvestment for R&D and stabilizes core earnings despite modest absolute margins.
Balance Sheet StrengthA prudent leverage profile and a healthy equity ratio provide financial flexibility to fund strategic initiatives and absorb shocks. This balance sheet strength supports long-term investment in manufacturing and R&D without immediate reliance on dilutive financing.
Specialized Business ModelA focused niche in injectable and infusion therapies creates structural advantages: specialized manufacturing expertise, higher barriers to entry, and deeper hospital relationships. This specialization supports defensible revenues and steady institutional demand over the medium term.
Bears Say
Negative Free Cash FlowSustained negative free cash flow and weak cash conversion materially constrain the company's ability to self-fund capex, R&D and dividends. Over months this raises the probability of external financing, tighter capital allocation, and limits resilience to adverse operational shocks.
Earnings Volatility (EPS Decline)A large negative EPS growth rate signals earnings instability despite revenue gains. Persistent EPS weakness can undermine retained earnings, reduce reinvestment capacity, and complicate long-term planning for dividends and strategic initiatives, increasing execution risk.
Moderate Operating MarginsRelatively modest EBIT and EBITDA margins limit cash flow cushions and competitive flexibility. Without structural efficiency gains or pricing power, margins may struggle against cost inflation and competitive pressures, constraining long-term profitability improvement.
Fuso Pharmaceutical Industries,Ltd. News
4538 FAQ
What was Fuso Pharmaceutical Industries,Ltd.’s price range in the past 12 months?
Fuso Pharmaceutical Industries,Ltd. lowest stock price was ¥2070.00 and its highest was ¥2530.00 in the past 12 months.
What is Fuso Pharmaceutical Industries,Ltd.’s market cap?
Fuso Pharmaceutical Industries,Ltd.’s market cap is ¥20.11B.
When is Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date?
Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date is May 12, 2026 which is in 21 days.
How were Fuso Pharmaceutical Industries,Ltd.’s earnings last quarter?
Fuso Pharmaceutical Industries,Ltd. released its earnings results on Feb 12, 2026. The company reported ¥99.84 earnings per share for the quarter, beating the consensus estimate of N/A by ¥99.84.
Is Fuso Pharmaceutical Industries,Ltd. overvalued?
According to Wall Street analysts Fuso Pharmaceutical Industries,Ltd.’s price is currently Overvalued.
Does Fuso Pharmaceutical Industries,Ltd. pay dividends?
Fuso Pharmaceutical Industries,Ltd. pays a Semiannually dividend of ¥45 which represents an annual dividend yield of 3.71%. See more information on Fuso Pharmaceutical Industries,Ltd. dividends here
What is Fuso Pharmaceutical Industries,Ltd.’s EPS estimate?
Fuso Pharmaceutical Industries,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuso Pharmaceutical Industries,Ltd. have?
Fuso Pharmaceutical Industries,Ltd. has 9,451,169 shares outstanding.
What happened to Fuso Pharmaceutical Industries,Ltd.’s price movement after its last earnings report?
Fuso Pharmaceutical Industries,Ltd. reported an EPS of ¥99.84 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.465%.
Which hedge fund is a major shareholder of Fuso Pharmaceutical Industries,Ltd.?
Currently, no hedge funds are holding shares in JP:4538
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Options Prices
Currently, No data available
---